LivaNova (NASDAQ:LIVN) Upgraded by StockNews.com to “Strong-Buy” Rating

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research report released on Friday.

A number of other research firms have also commented on LIVN. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Thursday, October 31st. Mizuho lowered their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Stock Down 0.7 %

Shares of LIVN traded down $0.35 during trading hours on Friday, hitting $51.63. 341,476 shares of the company were exchanged, compared to its average volume of 485,166. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market cap of $2.80 billion, a PE ratio of 122.93 and a beta of 1.01. The firm’s 50 day moving average is $51.37 and its 200-day moving average is $53.05. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.47.

Hedge Funds Weigh In On LivaNova

Several institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. BNP Paribas Financial Markets increased its position in shares of LivaNova by 88.6% during the first quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock valued at $2,356,000 after purchasing an additional 19,783 shares during the period. Texas Permanent School Fund Corp increased its holdings in LivaNova by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 47,147 shares of the company’s stock valued at $2,637,000 after buying an additional 620 shares during the period. Quantbot Technologies LP acquired a new position in shares of LivaNova in the 1st quarter valued at $994,000. Headlands Technologies LLC lifted its holdings in shares of LivaNova by 287.3% during the 1st quarter. Headlands Technologies LLC now owns 6,999 shares of the company’s stock worth $392,000 after acquiring an additional 5,192 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in shares of LivaNova by 4.7% during the 1st quarter. ProShare Advisors LLC now owns 12,378 shares of the company’s stock worth $692,000 after acquiring an additional 561 shares during the period. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.